Who Paid My Doc
David Gent
Podiatrist, Foot & Ankle Surgery Bremerton, WA Doctor of Podiatric Medicine
NPI 1205818069 CMS profile 191153
900 Sheridan Rd, Suite 101, Bremerton, WA 98310
General payments
$15,171
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, David Gent of Bremerton, WA is reported in the CMS Open Payments database as having received $15,171 across 121 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 89th percentile of Podiatrist, Foot & Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $2,387 | 21 | |
| 2024 | General | $1,403 | 30 | |
| 2023 | General | $1,566 | 15 | |
| 2022 | General | $1,071 | 9 | |
| 2021 | General | $4,767 | 20 | |
| 2020 | General | $1,777 | 11 | |
| 2019 | General | $2,199 | 15 |
Beside peers
- David Gent
- Podiatrist, Foot & Ankle Surgery median
- Middle half of Podiatrist, Foot & Ankle Surgery
- National median
In program year 2025, general payments to David Gent were reported at $2,387. Among 6,994 Podiatrist, Foot & Ankle Surgery profiles paid that year, the median was $424 and the middle half received between $139 and $1,306.
Show as a table
| Year | David Gent | Podiatrist, Foot & Ankle Surgery median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $2,199 | $389 | $118–$1,406 | $163 |
| 2020 | $1,777 | $191 | $62–$691 | $114 |
| 2021 | $4,767 | $329 | $104–$1,341 | $132 |
| 2022 | $1,071 | $419 | $125–$1,611 | $149 |
| 2023 | $1,566 | $377 | $128–$1,164 | $160 |
| 2024 | $1,403 | $394 | $134–$1,168 | $164 |
| 2025 | $2,387 | $424 | $139–$1,306 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 16 drugsPart D claims
401
Drug cost
$8,943
Branded share of claims
31.9%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Griseofulvin Ultramicrosize | Generic | 18 | $2,447 | |
| Pregabalin | Generic | 27 | $2,313 | |
| Ciclopirox Ciclopirox Olamine | Brand | 63 | $1,020 | |
| Gabapentin | Generic | 61 | $542 | |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | Brand | 51 | $541 | |
| Ketoconazole | Generic | 15 | $524 | |
| Diclofenac Sodium | Generic | 14 | $392 | |
| Terbinafine Hcl | Generic | 24 | $360 | |
| Cephalexin | Generic | 24 | $190 | |
| Mupirocin | Generic | 21 | $152 |
The 10 drugs with the highest cost, of 16 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 81 billing codesPaid by Medicare
$200,770
Medicare patients
429
Services billed
2,991
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Diabetes | 51% | |
| Arthritis | 49% | |
| Chronic kidney disease | 29% | |
| Ischemic heart disease | 24% | |
| Atrial fibrillation | 22% | |
| Depression | 21% | |
| Heart failure | 20% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 | Office | 14 | 37 | $200 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 | Office | 14 | 36 | $25 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
121 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Podiatrist, Foot & Ankle Surgery in Washington
Jeffrey Christensen
Podiatrist, Foot & Ankle Surgery · Everett, WA
Craig Clifford
Podiatrist, Foot & Ankle Surgery · Federal Way, WA
Shawn Khademi
Podiatrist, Foot & Ankle Surgery · Renton, WA
Gregory Grabowski
Podiatrist, Foot & Ankle Surgery · Bellevue, WA
Jacob McLeod
Podiatrist, Foot & Ankle Surgery · Longview, WA
Garrett Peresko
Podiatrist, Foot & Ankle Surgery · Morton, WA
Related records
Podiatrist, Foot & Ankle Surgery in Washington
Practitioners in the same specialty and state, ranked by reported value.
All Podiatrist, Foot & Ankle Surgery
Everyone recorded under this specialty, nationwide.
Doctors in Washington
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.